End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
14.77 CNY | -1.99% | -1.34% | -37.18% |
04-26 | Walvax Biotechnology's Profit Drops 92%, Operating Income Slids 28% in Q1 2024 | MT |
04-25 | Walvax Biotechnology's Unit to End COVID-19 Vaccine Trial | MT |
ETFs positioned on Walvax Biotechnology Co., Ltd.
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.09% | 2 M€ | -12.08% | - | |
0.54% | 2 M€ | -14.14% | ||
0.23% | 35 M€ | -5.85% | - | |
0.01% | 4 M€ | -4.41% | - | |
0.00% | 112 M€ | +4.66% | - | |
0.00% | 153 M€ | +6.72% | - | |
0.00% | 454 M€ | +8.54% | - | |
0.00% | 2,867 M€ | +9.56% | - | |
0.00% | 32 M€ | +7.81% | - | |
0.00% | 391 M€ | +8.36% | - | |
0.00% | 34 M€ | +8.28% | - | |
0.00% | 39 M€ | +5.65% | - | |
0.00% | 306 M€ | +5.75% | - | |
0.00% | 34 M€ | +3.48% | - | |
0.00% | 105 M€ | +3.29% | - | |
0.00% | 17 M€ | +2.84% | - | |
0.00% | 7 M€ | +5.02% | - | |
0.00% | 54 M€ | +0.26% | - |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.18% | 3.27B | |
-2.47% | 89.37B | |
+2.76% | 40.65B | |
-13.80% | 32.81B | |
+51.20% | 25B | |
-16.75% | 15.29B | |
-42.60% | 11.61B | |
-12.82% | 11.49B | |
+5.62% | 8.98B | |
-7.72% | 8.23B |
- Stock Market
- Equities
- 300142 Stock
- Funds and ETFs Walvax Biotechnology Co., Ltd.